Loading patent…
AssigneePiramal Enterprises Limited
InventorsVeena Agarwal, Arun Balakrishnan, Giridharan Periyasamy
Estimating the term…
The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.
1-20. (canceled)
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CDK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof, and a therapeutically effective amount of an antineoplastic agent selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel, and cetuximab, wherein in Formula I Ar is 2-chloro-phenyl or 2-chloro-4-trifluoromethyl phenyl:
Dependencies are inferred from the claim text.